- Kathleen Sebelius cites pharmacists' importance as Rite Aid CEO introduces Obamacare resource program
- On the heels of Q3, Walgreens outlines shift in front-end strategy and pharmacy tailwinds looking forward
- New Rite Aid group VP pharmacy initiatives and clinical services to oversee Wellness Ambassador program
- Senate passes Drug Quality and Security Act
- Rite Aid posts third consecutive quarterly profit as company expands Wellness+
NEW YORK — Stiefel has launched a new drug for treating acne, the company said Tuesday.
Stiefel, which is a subsidiary of British drug maker GlaxoSmithKline, announced the launch of Fabior (tazarotene) foam, which it called the only retinoid in a topical foam formulation for acne vulgaris in patients aged 12 and older.
The drug originally received Food and Drug Administration approval in May 2012.
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.